

Chloroform associated with bone mineral density and bone mineral content in adults: a population-based cross-sectional research.

1 **Lin Li^{1¶}, XK Liu^{2¶}, Xia Zhang^{3¶}, Yan Zhang^{3¶}, Qing Li^{3¶}, HF Geng², Li Shi², Ben**
2 **Wang², QQ Qiu², TP Yu², YQ Sang², LY Wang², Wei Xu^{2*}, Jun Liang^{1, 2*}**

3 ¹Graduate School of Bengbu Medical College, Bengbu, Anhui, China.

4 ²Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Institute of Medical
5 Sciences, Xuzhou Clinical School of Nanjing Medical University, Affiliated Hospital
6 of Medical School of Southeast University, Jiangsu, China.

7 ³Xuzhou Medical University, Xuzhou, Jiangsu, China.

First-author:

9 Lin Li, email: 1621561732@qq.com

Co-authors:

11 XK Liu, email: liuxuekui314@126.com

12 Xia Zhang, email: garnele99@163.com

13 Yan Zhang, email: zhangyan202103@126.com

14 Qing Li, email: 769798497@qq.com

15 HF Geng, email: genghoufa@njmu.edu.cn

16 Li Shi, email: shili2006_2009@126.com

17 Ben Wang, email: wangben1210@126.com

18 QQ Qiu, email: qq18796249070@163.com

19 TP Yu, email: yutianpei1188@163.com

20 YQ Sang, email: sangyiquan86@163.com

21 LY Wang, email: 786773733@qq.com

22 [¶]These authors contributed equally to this work.

*** Correspondence:**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 Jun Liang, email: mwlj521@njmu.edu.cn
- 25 Wei Xu, email: weixu159357@njmu.edu.cn

26 **Abstract**

27 **Background:** According to a recent cross-sectional study, reduced Bone Mineral
28 Density (BMD) in U.S. adults is associated with co-exposure to several Volatile
29 Organic Compounds (VOCs), and contact with VOCs increases the risk of developing
30 osteoporosis. However, the relationship between chloroform (an essential VOC
31 component) and BMD remains unclear. Consequently, we aimed to explore the
32 relationship between chloroform alone and Bone Mineral Density or Bone Mineral
33 Content (BMD or BMC).

34 **Methods:** Herein, 2,553 individuals aged 18 and above from the National Health
35 and Nutrition Examination Surveys (NHANES) in 2009-2010, 2013-2014, and 2017-
36 2020, were included. We employed two independent t-tests and multi-linear regression
37 models to statistically assess the relationship between chloroform exposure and
38 BMD/BMC in the spine and femoral area.

39 **Results:** A "V"-shaped correlation between chloroform exposure and BMD/BMC
40 was observed in the unadjusted model, particularly in the Ward's triangle and femoral
41 neck as a whole. A negative correlation was specifically observed for the Ward's
42 triangle BMD/BMC and L4 BMD/BMC. On the other hand, in the adjusted model, a
43 dominantly negative correlation between the L4 BMC and chloroform exposure was
44 observed over a range of exposure levels. The subgroup analysis revealed a negative
45 correlation between chloroform concentrations and BMC in the femur and spine,
46 especially in women and the 65-80 age population.

47 **Conclusion:** Our study revealed a "V" shaped correlation between chloroform and
48 BMD/BMC of the femur and spine in U.S. adults. This finding highlights the fact that
49 prolonged exposure to chloroform may increase the risk of developing osteoporosis.

50 **Introduction:**

51 Osteoporosis is a frequent bone disease characterized by reduced bone volume,
52 microstructural degeneration, and fragility fractures [1]. Fragility fractures, particularly
53 in the most vulnerable areas, including the vertebrae, hip, and forearm, are one of the
54 severe complications of osteoporosis. According to reports [2,3], fragility fractures can
55 cause emotional distress, reduced quality of life, and an increased socioeconomic
56 burden. Approximately 79,000 people in the United Kingdom suffer hip fractures
57 annually, with the cost in 2010 estimated at £3.5 billion and expected to rise to £5.5
58 billion each year by 2025, implying that osteoporosis will be a significant challenge in
59 the future and its burden on the medical community must be removed [4]. According
60 to osteoporosis research, enhancing Bone Mineral Density (BMD) is closely linked to
61 decreasing the risk of vertebral and non-vertebral fractures [5]. Many factors, including
62 aging, femininity, estrogen metabolism disturbances, and physical inactivity, are
63 critical in lowering BMD and have been implicated in the pathogenesis of osteoporosis
64 [6,7].

65 People are frequently exposed to Volatile Organic Compounds (VOCs) such as
66 chloroform, bromoform, dibromochloromethane, and dichlorobromomethane. The
67 increased contact is due to the widespread use of disinfectants, as these VOCs are
68 produced when disinfectants react with organic substances in water sources [8, 9, 10].

69 Compared to normal mice, the U.S. National Toxicology Program noted an increased
70 incidence of sternal dysplasia in bromoform-exposed mice [11]. Other studies
71 discovered a connection between VOC exposure and bone-healing-related chemokines,
72 with a downregulated osteoblast chemokine CXCL12 expression after exposure to
73 benzene or its derivatives, and that CCL2 (a chemokine essential for osteoclast
74 formation) production was induced by chlorobenzene exposure [12, 13, 14]. These
75 findings imply that VOCs could impact BMD levels by affecting osteoblast activity.
76 Additionally, individual and combined VOC exposure was found to be associated with
77 lower BMD in U.S. adults, and Alkaline Phosphatase (ALP), Body Mass Index (BMI),
78 Fasting Insulin (F.I.), and High-Density Lipoprotein (HDL) were shown to be
79 intermediaries in VOC and BMD co-exposure [15]. Chloroform, a significant member
80 of VOCs, is strongly absorbed through the pulmonary, oral, and dermal pathways and
81 is linked with several acute and chronic illnesses, including neurological, respiratory,
82 hepatic, and renal dysfunctions, reproductive abnormalities, and digestive or urinary
83 malignancies [16, 17]. However, the connection between blood chloroform and
84 BMD/BMC was rarely investigated alone in past studies.

85 This research aimed to explore the relationship between blood chloroform and
86 BMD/BMC using data from the National Health and Nutrition Examination Survey
87 (NHANES). We, therefore, obtained femur BMD/BMC and spine BMD/BMC datasets
88 published in 2009-2010, 2013-2014, and 2017-2020 from NHANES.

89 **Materials and methods**

90 **Study design and participants**

91 Herein, data from the NHANES, a cross-sectional survey of more than 5,000
92 respondents conducted yearly by the Center for Disease Control and Prevention's (CDC)
93 Center for Health Statistics, was used. We specifically used NHANES data from 2009-
94 2010, 2013-2014, and 2017-2020. We selected 22,333 adults (of whom 6,227 had blood
95 chloroform data) from 36,272 available subjects. Subsequently, 2637 individuals with
96 femur and spine Dual-Energy X-ray Absorptiometry (DEXA) data were selected. After
97 excluding patients with a history of osteoporosis treatment, 2553 subjects aged ≥ 18
98 years were included in the final statistical analysis. **Fig1** depicts the flowchart for
99 participant exclusion. (**Fig1**: Flowchart for Screening Research Subjects)

100 **Variables**

101 In this study, we used blood chloroform concentration as the exposure variable.
102 Chloroform concentration in the blood was analyzed using Capillary Gas
103 Chromatography (G.C.) and Mass Spectrometry (M.S.) with Selected Ion Monitoring
104 (SIM) detection and isotope dilution. The chloroform detection limits ranged from
105 0.00148 to 0.602 ng/ml, and for lower LLOD (Lower Limit of Detection) values, an
106 interpolated LLOD value divided by the square root of 2 was used. The dependent
107 variables were the femoral and spinal Bone Mineral Density (BMD) and Bone Mineral
108 Content (BMC). In Shepherd's laboratory, Dual-Energy X-ray Absorptiometry (DXA)
109 was used to measure the spine and femur BMC, whereas the Hologic software APEX
110 v4.0 (Hologic) sector beam densitometry was used to scan and calculate the spine and
111 femur BMC and BMD. All variables included as covariates in the study are listed below:

112 Gender (male, female), Race/ethnicity (Mexican-American, Non-Hispanic white, Non-
113 Hispanic black, other Hispanic, other race), Household Poverty-Income Ratio (PIR by
114 poverty line: values 0 to 0.99 indicate below poverty, ≥ 1.00 indicate poverty or above
115 poverty)[18], Excessive alcohol consumption (>1 drink /day for women or >2 drinks
116 /day for men (in the past 12 months)), Hypertension (blood pressure $\geq 140/90$ mmHg or
117 taking anti-hypertensive medication), Diabetes mellitus (self-reported diabetes history,
118 Fasting Blood Glucose (FPG) level ≥ 7.0 mmol/L, HbA1c $\geq 6.5\%$ or taking anti-diabetic
119 medication), Arthritis, Cardiovascular disease (self-reported congestive heart failure,
120 coronary artery disease, heart attack or stroke history), Thyroid problems (self-reported
121 hyperthyroidism, hypothyroidism, thyroiditis), COPD(Chronic Obstructive Pulmonary
122 Disease), Smoking (self-described as having smoked ≥ 100 cigarettes in a lifetime),
123 History of osteoporosis treatment and osteopenia (Bone Mineral Density (BMD) T-
124 score ≤ -2.5 in lumbar spine or femoral neck) [19]. Age, body weight, abdominal
125 circumference, and BMI were all continuous covariates in our analysis. The blood
126 chloroform, BMD, BMC, and covariance data were obtained from the NHANES
127 website.

128 **Statistical analysis**

129 Statistical analyses were conducted using R software (version 3.6.1), IBM SPSS
130 version 25(IBM, Armonk, New York, USA), and GraphPad Prism9. The mean and
131 Standard Deviation (S.D.) values were used for variables with continuous features,
132 whereas categorical variable represented frequency. The Spearman correlation test
133 was used to assess differences between the classification variables in the exposure

134 group. The Kruskal-Wallis test or one-way ANOVA was used to examine differences
135 in continuous variables between groups. Blood chloroform levels were grouped into
136 tertiles (tertile 1: <33%, tertile 2: 33-66%, tertile 3: >66%) and univariate and
137 multivariate linear regression models were tested to analyze the relationship between
138 the different blood chloroform categories. We adjusted the confounding variables in
139 the multi-linear regression model to investigate the correlation between blood
140 chloroform levels and BMD/BMC (femoral and spine). These included Model 1 (the
141 unprecedented model), Model 2 (for gender, age, race, and BMI adjustment), and
142 Model 3 (for gender, age, race, BMI, osteoporosis, COPD, and thyroid problems
143 adjustments, and further adjustment for arthritis, smoking and excessive drinking).
144 Regression analysis results were expressed as β (beta) coefficients, 95% confidence
145 intervals, and statistically significant P values (P values<0.05).

146 **Results**

147 **Subjects characteristics**

148 This study had 2553 participants (1288 women and 1265 men). Based on the femoral
149 and spinal DEXA data, the average age of the participants and the average chloroform
150 levels in their whole blood was 48.83 years and 0.0171 ± 0.0182 ng/mL (ranging from
151 0.0021 to 0.1790 ng/mL), respectively. The weighted characteristics of these
152 participants based on the third-class classification are shown in **TableS1**. According to
153 the femoral and spine DEXA data, differences among groups in baseline variables such
154 as age, race, height, BMI, waist circumference, hypertension, arthritis, thyroid illnesses,
155 and smoking were statistically significant (P<0.05).

156 **Connection between chloroform and BMD**

157 **Tables1-2** and **S2** illustrate the results. Blood chloroform concentration by tertile had
158 a statistically significant relationship with total femoral BMD ($P < 0.05$); femoral neck
159 BMD ($P < 0.01$); rotor BMD ($P < 0.05$); inter-rotor BMD ($P < 0.05$); Ward's triangle
160 BMD ($P < 0.01$); and L4 BMD ($P < 0.01$).

161 The multiple linear regression models and weighted univariate analyses are
162 detailed in **Tables1-2**. All regressions were conducted before adjusting for some of the
163 covariates (model 1), except for total spine BMD (β -0.0020; 95% CI -0.0051, 0.0011),
164 L1 BMD (β 0.0004; 95% CI -0.0030, 0.0039), L2 BMD (β - 0.0024; 95% CI -0.0057,
165 0.0009), and L3 BMD (β -0.0016; 95% CI -0.0048, 0.0016). A statistically significant
166 correlation existed between increased blood chloroform concentration and total femoral
167 BMD, femoral neck BMD, rotor BMD, inter-rotor BMD, Ward's triangle BMD, and
168 L4 BMD ($P < 0.05$). The L4 BMD was negatively correlated with blood chloroform
169 levels after adjusting for some covariates (model 2). After adjusting for more relevant
170 covariates simultaneously (model 3), L4 BMD decreased with rising blood chloroform
171 levels, but not at other sites.

Table1: The relationship between blood chloroform and BMD/BMC in the femur

		Model1 β(95%CI) value	Model2 β(95%CI) P value	Model3 β(95%CI) P value
Total femur BMD(g/cm2) *	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0014(-0.0054,0.0083)0.681	0.0043(-0.0012,0.0098)0.123	0.0047(-0.0007,0.0102)0.090
	Q2 : 0.00875-0.01690ng/ml	-0.0082(-0.0150,-0.0014)0.019	Reference	-0.0029(-0.0084,0.0026)0.308
Total femur BMC(g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0034(-0.0075,0.0144)0.542	0.0021(-0.0052,0.0094)0.574	0.0024(-0.0049,0.0097)0.520
	Q2 : 0.00875-0.01690ng/ml	-0.0142(-0.0252,-0.0033)0.011	-0.0060(-0.0133,0.0014)0.112	-0.0064(-0.0138,0.0009)0.087
Femoral neck BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	-0.0071(-0.0148,0.0005)0.070	-0.0005(-0.0066,0.0056)0.876	-0.0001(-0.0062,0.0060)0.983
	Q2 : 0.00875-0.01690ng/ml	-0.0089(-0.0166,-0.0012)0.024	-0.0004(-0.0066,0.0057)0.889	-0.0011(-0.0073,0.0050)0.714
Femoral neck BMC(g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	-0.0055(-0.0147,0.0037)0.238	-0.0009(-0.0076,0.0058)0.789	-0.0006(-0.0073,0.0061)0.871
	Q2 : 0.00875-0.01690ng/ml	-0.0142(-0.0233,-0.0051)0.002	-0.0040(-0.0107,0.0028)0.249	-0.0046(-0.0113,0.0021)0.182
Trochanter BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0031(-0.0043,0.0106)0.411	0.0055(-0.0008,0.0119)0.089	0.0060(-0.0004,0.0123)0.065
	Q2 : 0.00875-0.01690ng/ml	-0.0090(-0.0164,-0.0015)0.018	-0.0037(-0.0101,0.0026)0.250	-0.0045(-0.0109,0.0019)0.164
Trochanter BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0070(-0.0050,0.0189)0.253	0.0037(-0.0051,0.0124)0.409	0.0040(-0.0051,0.0127)0.371
	Q2 : 0.00875-0.01690ng/ml	-0.0116(-0.0234,0.0005)0.059	-0.0053(-0.0140,0.0035)0.239	-0.0057(-0.0145,0.0030)0.198
Intertrochanter BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0032(-0.0035,0.0100)0.349	0.0054(-0.0001,0.0110)0.055	0.0058(-0.0003,0.0114)0.039
	Q2 : 0.00875-0.01690ng/ml	-0.0070(-0.0138,-0.0002)0.043	-0.0016(-0.0072,0.0040)0.566	-0.0021(-0.0077,0.0034)0.445
Intertrochanter BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0038(-0.0078,0.0154)0.521	0.0021(-0.0057,0.0099)0.596	0.0024(-0.0054,0.0102)0.547
	Q2 : 0.00875-0.01690ng/ml	-0.0151(-0.0267,-0.0036)0.010	-0.0064(-0.0143,0.0014)0.107	-0.0068(-0.0147,0.0010)0.086
Wards triangle BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	-0.0116(-0.0241,0.0009)0.069	0.0059(-0.0037,0.0155)0.228	0.0068(-0.0027,0.0163)0.162
	Q2 : 0.00875-0.01690ng/ml	-0.0184(-0.0301,-0.0059)0.004	-0.0002(-0.0098,0.0094)0.962	-0.0017(-0.0113,0.0078)0.725
Wards triangle BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	-0.0117(-0.0253,0.0019)0.091	0.0073(-0.0032,0.0179)0.172	0.0083(-0.0022,0.0188)0.120
	Q2 : 0.00875-0.01690ng/ml	-0.0209(-0.0345,-0.0074)0.002	-0.0023(-0.0129,0.0083)0.666	-0.0040(-0.0145,0.0065)0.457

Model 1: no covariates were adjusted; Model 2: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

*Logarithmic conversion of all BMD/BMC data.

172

173

Table2: The relationship between blood chloroform and BMD/BMC in the spine

		Model1 β(95%CI) value	Model2 β(95%CI) P value	Model3 β(95%CI) P value
Total spine BMD(g/cm2)*	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0018(-0.0045,0.0082)0.572	0.0023(-0.0037,0.0082)0.456	0.0024(-0.0035,0.0083)0.424
	Q2 : 0.00875-0.01690ng/ml	-0.0054(-0.0118,0.0009)0.093	-0.0049(-0.0109,0.0010)0.106	-0.0050(-0.0109,0.0010)0.100
Total spine BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0036(-0.0062,0.0135)0.471	0.0027(-0.0059,0.0113)0.535	0.0029(-0.0057,0.0114)0.510
	Q2 : 0.00875-0.01690ng/ml	-0.0110(-0.0208,-0.0012)0.028	-0.0080(-0.0166,0.0006)0.068	-0.0080(-0.0165,0.0006)0.068
L1 BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0039(-0.0030,0.0108)0.266	0.0040(-0.0023,0.0103)0.211	0.0042(-0.0021,0.0104)0.194
	Q2 : 0.00875-0.01690ng/ml	-0.0014(-0.0083,0.0055)0.695	-0.0002(-0.0066,0.0061)0.941	-0.0002(-0.0065,0.0061)0.951
L1 BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0083(-0.0026,0.0191)0.136	0.0053(-0.0038,0.0144)0.251	0.0054(-0.0036,0.0144)0.241
	Q2 : 0.00875-0.01690ng/ml	-0.0030(-0.0138,0.0079)0.592	-0.0001(-0.0092,0.0090)0.986	0.0002(-0.0089,0.0093)0.970
L2 BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0007(-0.0060,0.0073)0.839	0.0020(-0.0042,0.0081)0.533	0.0021(-0.0040,0.0082)0.498
	Q2 : 0.00875-0.01690ng/ml	-0.0062(-0.0128,0.0004)0.066	-0.0045(-0.0107,0.0017)0.155	-0.0046(-0.0107,0.0016)0.147
L2 BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0054(-0.0048,0.0157)0.297	0.0045(-0.0042,0.0133)0.310	0.0046(-0.0041,0.0133)0.297
	Q2 : 0.00875-0.01690ng/ml	-0.0118(-0.0220,-0.0016)0.023	-0.0078(-0.0166,0.0010)0.082	-0.0076(-0.0164,0.0011)0.086
L3 BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0012(-0.0053,0.0077)0.719	0.0017(-0.0045,0.0079)0.595	0.0018(-0.0043,0.0079)0.566
	Q2 : 0.00875-0.01690ng/ml	-0.0050(-0.0115,0.0015)0.130	-0.005(-0.0113,0.0011)0.105	-0.0052(-0.0113,0.0010)0.101
L3 BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.005517(-0.0042,0.0153)0.267	0.0048(-0.0039,0.0135)0.281	0.0049(-0.0037,0.0136)0.263
	Q2 : 0.00875-0.01690ng/ml	-0.0116(-0.0213,-0.0019)0.020	-0.0091(-0.0178,-0.0004)0.040	-0.0092(-0.0178,-0.0005)0.038
L4 BMD(g/cm2)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0023(-0.0043,0.0088)0.494	0.0020(-0.0042,0.0083)0.527	0.0022(-0.0040,0.0084)0.489
	Q2 : 0.00875-0.01690ng/ml	-0.0073(-0.0138,-0.0008)0.028	-0.0078(-0.0140,-0.0015)0.015	-0.0079(-0.0141,-0.0017)0.013
L4 BMC (g)	Chloroform (ng/mL)	Reference	Reference	Reference
	Q1 : 0.00210-0.00874ng/ml	0.0015(-0.0083,0.0114)0.758	0.0004(-0.0085,0.0093)0.926	0.0006(-0.0082,0.0095)0.889
	Q2 : 0.00875-0.01690ng/ml	-0.0145(-0.0243,-0.0047)0.004	-0.0128(-0.0217,-0.0039)0.005	-0.0129(-0.0218,-0.0041)0.004

Model 1: no covariates were adjusted; Model 2: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

*Logarithmic conversion of all BMD/BMC data.

174

175

176

Connection between chloroform and BMC

177

Detailed results are presented in Tables 1-2 and S2. Weighted univariate and multiple

178 linear regression analyses are illustrated in Tables 1-2. In model 1, blood chloroform
179 levels were categorized by tertile, except for rotor BMC (β -0.0023; 95% CI -0.0066,
180 0.0021), and L1 BMC (β -0.0004; 95% CI -0.0058, 0.0049). There was a negative
181 correlation between increased blood chloroform concentrations and BMC at several
182 sites, including total femoral BMC, femoral neck BMC, Intertrochanter BMC, Ward's
183 triangle BMC, total spine BMC, L2 BMC, L3 BMC, and L4 BMC. Additionally,
184 increased blood chloroform concentrations in the femur and spine were negatively
185 correlated with BMC ($P < 0.05$). The L3 BMC and L4 BMC were negatively correlated
186 with blood chloroform levels after adjusting for some covariates (model 2). Finally, in
187 model 3, L3 BMC and L4 BMC decreased with increasing blood chloroform
188 concentration.

189 **Subgroup analysis**

190 The findings of subgroup analyses adjusted for associated covariates are shown in
191 **Tables 3-5**. According to the Multiple regression analysis in the femoral area, the
192 femoral neck BMC blood chloroform level decreased in the male gender (β -0.0059; 95
193 % CI -0.0115, -0.0002; $P < 0.05$). According to the analysis by race as a subgroup, the
194 femoral neck BMD/BMC in Non-Hispanic White and other Race-Including Multi-
195 Racial subjects exhibited a negative correlation with blood chloroform concentration
196 ($P < 0.05$). In contrast, no meaningful correlation between blood chloroform and BMD
197 or BMC was observed in Mexican-American, Non-Hispanic Black, and Other Hispanic
198 subjects. A negative correlation between blood chloroform and femoral neck
199 BMD/BMC was revealed by the results stratified by age but only in the 65-80 years-

200 old participants (β -0.0100; 95% CI -0.0186, -0.0014; $P < 0.05$); (β -0.0144; 95% CI -
 201 0.0234, -0.0054; $P < 0.05$).

Table3 Association of blood chloroform with femur neck BMD/BMC, stratified by sex, race/ethnicity and age.

	femur neckBMD (g/cm ²)	β (95%CI) value	femur neck (g)	β (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0073,0.0033)	0.454	-0.0045(-0.0100,0.0011)	0.114
female	-0.0046(-0.0100,0.0008)	0.094	-0.0059(-0.0115,-0.0002)	0.041
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0020(-0.0098,0.0058)	0.617	-0.0041(-0.0139,0.0058)	0.416
Other Hispanic	-0.0052(-0.0163,0.0060)	0.361	-0.0079(-0.0215,0.0057)	0.253
Non-Hispanic White	-0.0075(-0.0135,-0.0015)	0.015	-0.0086(-0.0158,-0.0015)	0.018
Non-Hispanic Black	-0.0086(-0.0178,0.0006)	0.0664	-0.0104(-0.0211,0.0003)	0.056
Other Race—Including Multi-Racial	-0.0119(-0.0242,0.0003)	0.056	-0.0171(-0.0324,-0.0018)	0.028
Subgroup analysis stratified by age				
18-45	0.0034(-0.0010,0.0078)	0.126	0.0018(-0.0031,0.0066)	0.478
45-65	0.0016(-0.0032,0.0064)	0.517	-0.0006(-0.0058,0.0047)	0.832
65-80	-0.0100(-0.0186,-0.0014)	0.022	-0.0144(-0.0234,-0.0054)	0.002

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

202

203

Table4 Association of blood chloroform with wards triangle BMD/BMC, stratified by sex, race/ethnicity and age.

	Wards triangle BMD (g/cm ²)	β (95%CI) value	Wards triangleBMC (g)	β (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0110,0.0069)	0.658	-0.0023(-0.0118,0.0072)	0.634
female	-0.0118(-0.0204,-0.0032)	0.007	-0.0144(-0.0239,-0.0049)	0.003
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0024(-0.0148,0.0100)	0.703	-0.0036(-0.0172,0.0100)	0.605
Other Hispanic	-0.0068(-0.0244,0.0109)	0.451	-0.0090(-0.0281,0.0102)	0.358
Non-Hispanic White	-0.0124(-0.0224,-0.0024)	0.015	-0.0136(-0.0244,-0.0027)	0.015
Non-Hispanic Black	-0.0133(-0.0286,0.0021)	0.091	-0.0153(-0.0318,0.0012)	0.070
Other Race—Including Multi-Racial	-0.0103(-0.0293,0.0087)	0.289	-0.0118(-0.0324,0.0089)	0.2639
Subgroup analysis stratified by age				
18-45	0.0037(-0.0025,0.0099)	0.241	0.0018(-0.0052,0.0088)	0.616
45-65	0.0052(-0.0023,0.0128)	0.175	0.0049(-0.0034,0.0131)	0.251
65-80	-0.0065(-0.0211,0.0081)	0.381	-0.0060(-0.0216,0.0095)	0.447

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

204

205

Table5 Association of blood chloroform with L4 BMD/BMC, stratified by sex, race/ethnicity and age.

	L4BMD (g/cm ²)	β (95%CI) value	L4BMC (g)	β (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0012(-0.0057,0.0033)	0.600	-0.0034(-0.0098,0.0030)	0.297
female	-0.0044(-0.0090,0.0002)	0.060	-0.009(-0.0149,-0.0022)	0.009
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0055(-0.0125,0.0015)	0.124	-0.0107(-0.0217,0.0002)	0.054
Other Hispanic	-0.0028(-0.0124,0.0067)	0.560	-0.0058(-0.0204,0.0088)	0.437
Non-Hispanic White	-0.0044(-0.0093,0.0005)	0.082	-0.0078(-0.0152,-0.0005)	0.037
Non-Hispanic Black	-0.0066(-0.0142,0.0011)	0.095	-0.0109(-0.0223,0.0004)	0.059
Other Race—Including Multi-Racial	-0.0057(-0.0168,0.0054)	0.313	-0.0113(-0.0286,0.0059)	0.196
Subgroup analysis stratified by age				
18-45	0.0001(-0.0037,0.0039)	0.957	-0.0014(-0.0071,0.0043)	0.625
45-65	-0.0037(-0.0088,0.0014)	0.156	-0.0073(-0.0145,-0.0001)	0.047
65-80	-0.0072(-0.0162,0.0018)	0.119	-0.0154(-0.0282,-0.0026)	0.018

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

206

207 Results of the multiple regression analysis of Ward's triangle region revealed that

208 stratified by gender, female Ward's triangle BMD decreased while chloroform levels

209 increased and that female Ward's triangle BMC was negatively correlated with
210 chloroform. According to the results stratified by race, blood chloroform concentration
211 was negatively correlated with BMD/BMC except for Hispanic white subjects (β -
212 0.0124; 95%CI -0.0224, -0.0024; $P < 0.05$); (β -0.0136; 95% CI -0.0244, -0.0027;
213 $P < 0.05$). Additionally, although BMC was not statistically significant, chloroform
214 concentrations were correlated with BMD in Mexican-American, Other Hispanic, Non-
215 Hispanic Black and Other Race-Including Multi-Racial participants. The results
216 stratified by age revealed no statistically significant association between chloroform
217 concentrations and BMD and BMC at all femoral sites in all age groups.

218 Female L4 BMC decreased with increasing blood chloroform in the spinal region
219 following stratification by sex (β -0.009; 95% CI -0.0149, -0.0022; $P < 0.01$). When
220 stratified by race, we discovered a significant correlation between Non-Hispanic White
221 BMC and blood chloroform (β -0.0078; 95% CI -0.0152, -0.0005; $P < 0.05$).
222 Additionally, there was a significant negative correlation between BMC and
223 chloroform in the 45-65 and 65-80 age groups when age was used as a stratification
224 factor (β -0.0073; 95% CI -0.0145, -0.0001; $P < 0.05$); (β -0.0154; 95% CI -0.0282, -
225 0.0026; $P < 0.05$).

226 **Discussion**

227 Osteoporosis is a degenerative bone disease that increases the risk of fracture [20]. With
228 the aging population, osteoporosis is becoming a major public health concern
229 worldwide [21,22]. The current era of rapid global economic development
230 characterized by various industrial processes, including increased production of

231 automobiles, tobacco, cleaning products, building materials, and other household
232 products, has made VOCs more common in the human environment [23,24,25,26,27].
233 Several studies have demonstrated that some VOCs, such as Perfluoro and
234 Polyfluoroalkyl Substances (PFAS), Urinary Polycyclic Aromatic Hydrocarbons
235 (UPAHs), trichlorophenol, and many other organics are negatively associated with
236 BMD/BMC levels at specific sites in the human body [28,29,30]. The safety of urban
237 centralized water supply largely relies on water disinfection as it kills pathogens and
238 prevents waterborne infectious diseases [31]. However, water Disinfection Byproducts
239 (DBPs) mostly contain certain VOCs, including chloroform, bromine,
240 dibromochloromethane, and dichlorobromomethane, with chloroform presence being
241 exceptionally high in these DBPs [32]. A survey specifically focused on chloroform
242 was conducted in China to evaluate the health risks associated with municipal water
243 supply. It analyzed the distribution pattern and seasonal chloroform variation
244 characteristics in the municipal water supply in Xi'an and the average daily chloroform
245 exposure dose. According to the results, the average daily exposure dose of chloroform
246 in the Xi'an municipal water supply was 7.39×10^{-4} mg/(kg*d), with drinking water
247 consumption as the leading source for the non-carcinogenic risk of chloroform [33].
248 Another survey found that the carcinogenic risk of ten contaminants in city drinking
249 water, including chloroform, exceeded the acceptable level [34]. All these studies
250 indicate that chloroform could potentially harm human health, but no conclusive study
251 has proven the dangers of chloroform exposure to public safety. Although some studies
252 have associated chloroform co-exposure with bone health indicators [15], no link with

253 BMD has been reported. In our study, we hypothesize that there could be a connection
254 between blood chloroform and BMD/BMC. After adjusting for confounders, we
255 discovered a negative correlation between BMD/BMC and blood chloroform in L3
256 BMC and L4 BMD/BMC. Our analysis revealed a negative association between
257 chloroform and femoral neck BMD in participants aged 65-80 years and Non-Hispanic
258 White subjects, as well as Ward's triangle BMD in women and Non-Hispanic White
259 subjects. For BMC, a negative correlation was found between blood chloroform and
260 femoral neck BMC, Non-Hispanic White and Other Race-Including Multi-Racial
261 subjects femoral neck BMC, female Ward's triangular BMC, Ward's Triangular BMC
262 of female Non-Hispanic White and 65-80 years old subjects, Female L4 and Non-
263 Hispanic White Subjects BMC, and L4 BMC of 45-65 years and 65-80 years old
264 subjects.

265 Multiple linear regression analysis and analysis within the Asian group revealed
266 the relationship between blood chloroform and BMD/BMC in most areas of the femur
267 and spine before adjusting for confounding factors. However, after adjusting for
268 confounding variables, it was discovered that the correlation between blood chloroform
269 and femoral BMD/BMC was not as strong. This finding implies that the relationship
270 between blood chloroform and femoral BMD/BMC is largely influenced by age, gender,
271 and race. On the one hand, this phenomenon may be attributed to femur and lumbar
272 spine structures, which theoretically have the most substantial BMD changes in
273 postmenopausal women with a higher proportion of cancellous bone [35, 36, 37, and
274 38]. On the other hand, it could be attributed to the sample population's old age ($48.8 \pm$

275 16.8 years), where hormonal drugs used by some older individuals exert a greater
276 influence on femoral BMD/BMC than on lumbar spine BMD/BMC, making blood
277 chloroform less likely to be associated with femoral BMD/BMC [39]. Furthermore,
278 after adjusting for relevant covariates, stratified analysis by age, sex, and race revealed
279 that chloroform concentration was negatively correlated with BMC at most sites. Blood
280 chloroform concentration at L4 was significantly negatively correlated with BMC in
281 women in the subgroup analysis. Contrastingly, no correlation between chloroform
282 concentration and femoral or spinal BMC was observed in men, implying that blood
283 chloroform levels may have some predictive value for bone mass in women. This
284 phenomenon may be attributed to the sample population's older age (48.8 ± 16.8 years)
285 and the substantial decline in sex hormone levels in postmenopausal women resulting
286 in lower femoral BMD quantity. Men, on the other hand, showed no such specific
287 changes. We hypothesized that the varying sex hormone levels might influence the
288 femoral neck, Ward's triangle, or L4 BMC differently. Furthermore, the association
289 between blood chloroform and femoral and spinal BMC was closer than that of BMD,
290 which may be explained by the significant variations in the bone area resulting from
291 individual differences.

292 Both BMD and BMC have been shown by studies to be significant osteoporosis
293 indicators and to play a critical role in osteoporotic fracture development [40]. Our
294 study revealed a negative correlation between blood chloroform in some spine regions
295 and BMD/BMC. Chloroform is used as a solvent to soften material during endodontic
296 treatment, and case studies revealed that during the patients' endodontic retreatment

297 visit, chloroform was extruded through the perforation into the periodontal ligament
298 space, resulting in necrosis of the tooth-supporting bone [41]. Our findings on the
299 negative effect of chloroform on bone loss are consistent with another research which
300 discovered that organochlorine contaminants-exposure could impact fertility, the
301 menstrual cycle, and other aspects of the human reproductive system [42,43]. In a
302 pharmaceutical company, female personnel exposed to a mixture of organic solvents
303 (including chloroform) exhibited higher Thyroid-Stimulating Hormone (TSH) levels
304 than the non-exposed group, with a significant correlation between chloroform and
305 TSH levels [44]. According to some clinical studies, a positive correlation exists
306 between TSH and femoral and spinal BMD in early postmenopausal women [45].
307 Consequently, we speculate that chloroform may have a positive association with
308 BMD/BMC mediated by hormones *in vivo*, and this hypothesis is supported by the "V"-
309 shaped correlation between chloroform, and BMD/BMC discovered in our study (**Fig2-**
310 **3**). Additionally, we hope to find the link between chloroform and bone metabolism
311 through preliminary data analysis and further basic research. In this regard, our group
312 has already started collecting environmental exposure samples and establishing a
313 sample bank. (**Fig2-3:Restricted cubic spline plots between chloroform and femoral**
314 **neck BMC and chloroform and L4 BMC**)

315 With this cross-sectional research, we plan to further explore the effect of
316 chloroform exposure on BMD/BMC. Herein, we used raw data on blood chloroform
317 and femoral and spinal BMD/BMC from adults selected from NHANES in 2009-2010,
318 2013-2014, and 2017-2020 to perform a Restricted Cubic Splines (RCS) analysis of the

319 relationship between chloroform and BMD/BMC. The non-linear connection between
320 blood chloroform and spinal BMD/BMC revealed a "V" shaped correlation and a
321 statistically significant association between chloroform levels within the 0-0.02 ng/ml
322 range and spinal BMD/BMC (**Figure2-3**). According to the literature review in some
323 studies, chloroform harms BMD/BMC. Contrastingly, some studies suggest that
324 chloroform may have a positive association with BMD/BMC. However, no specific
325 reference in the literature demonstrates a clear connection between chloroform and
326 BMD/BMC; thus, more research is required to determine the optimal level of
327 chloroform exposure in relation to BMD/BMC levels. The above findings imply that
328 exposure to VOCs such as chloroform remains a major public health concern.
329 Disinfection byproducts are ubiquitous, and people (particularly older adults) with
330 prolonged exposure to the chloroform from these products must be especially aware of
331 their long-term risks.

332 **Limitation**

333 Our study had several limitations. First, the data used in this investigation was obtained
334 from NHANES, and therefore it was difficult to establish the exact timing between
335 chloroform exposure and changes in BMD. Consequently, we could only develop
336 correlations but not causality at this point. More research through prospective studies
337 is therefore required to investigate this further. Second, our data on subjects were
338 primarily from a single time point, making it difficult to determine the association
339 between chloroform and BMD/BMC over time, potentially leading to bias in
340 classifying specific populations. Third, some data were from self-reported

341 questionnaires, which may have resulted in recall or misclassification bias. Fourth,
342 missing whole-body skeletal BMD/BMC data impeded a comprehensive examination
343 of the chloroform and BMD/BMC correlation. Finally, the residual confounding
344 problem persisted despite employing multivariate adjustment techniques. We are
345 developing a cohort of VOC exposure (including chloroform) in our city and expect
346 that more convincing evidence elucidating the link between chloroform and
347 BMD/BMC will soon be available.

348 **Conclusion**

349 After adjustment for confounders, we established a "V" shaped correlation between
350 blood chloroform and femoral spine BMD/ BMC, with a negative correlation at 0-0.02
351 ng/ml ($p < 0.05$), especially for L4 BMC. Our research provides epidemiological
352 evidence for further investigation into the correlation between chloroform and BMD/
353 BMC.

354 **Acknowledgements**

355 This thesis would not have been possible without the consistent and valuable reference
356 materials that I received from my supervisor whose insightful guidance and enthusiastic
357 encouragement in the course of my shaping this thesis definitely gains my deepest
358 gratitude.

359 **References**

- 360 1. Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000
361 Mar;(372):139-50.10. doi:1097/00003086-200003000-00016

- 362 2. Farrah Z, Jawad AS. Optimising the management of osteoporosis. *Clinical*
363 *medicine* (London, England). 2020 Sep;20(5): e196-e201. doi:
364 10.7861/clinmed.2020-0131
- 365 3. Zhang R, Huang Q, Su G, Wei M, Cui Y, Zhou H, Song W, Di D, Liu J, Wang Q.
366 Association between multiple vitamins and bone mineral density: a cross-sectional
367 and population-based research in the NHANES from 2005 to 2006. *Population-*
368 *based research in the NHANES from 2005 to 2006. BMC Musculoskelet Disord.*
369 2023 Feb 10;24(1):113. doi: 10.1186/s12891-023-06202-6
- 370 4. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The
371 epidemiology of osteoporosis. *Br Med Bull.* 2020 May 15;133(1):105-117.
372 doi:10.1093/bmb/ldaa005
- 373 5. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley
374 JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density
375 and Reduction in Fracture Risk: A Meta-Regression of Published Trials. *J Bone*
376 *Miner Res.* 2019 Apr;34(4):632-642. doi:10.1002/jbmr.3641
- 377 6. Levin VA, Jiang X, Kagan R. Estrogen Therapy for osteoporosis in the modern
378 era. *Osteoporos Int.* 2018;29(5):1049-1055. doi: 10.1007/s00198-018-4414-z
- 379 7. Chen LR, Hou PH, Chen KH. Nutritional support and physical modalities for
380 people with osteoporosis: current opinion. *Nutrients.* 2019;11(12): 15. doi:
381 10.3390/nu11122848
- 382 8. Li Adela Jing, Pal Vineet Kumar, and Kannan Kurunthachalam. A review of
383 environmental occurrence, toxicity, biotransformation and biomonitoring of

- 384 volatile organic compounds." 3.(2021):91-116.
- 385 9. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al.
386 Exposure to volatile organic compounds - acrolein, 1,3-butanadiene, and
387 crotonaldehyde - is associated with vascular dysfunction. *environ res.* (2021)
388 196:110903. doi:10.1016/j.envres.2021.110903
- 389 10. Wei C, Chen Y, Yang Y, Ni D, Huang Y, Wang M, Yang X, Chen Z. Assessing
390 Volatile Organic Compounds Exposure and Prostate-specific Antigen: National
391 Health and Nutrition Examination Survey, 2001-2010. *Front Public Health.* 2022
392 Jul 29; 10: 957069. doi:10.3389/fpubh.2022.957069
- 393 11. National Toxicology Program. NTP toxicology and carcinogenesis studies of
394 methyl bromide (CAS: 74-83-9) in B6C3F1 mice (inhalation studies). *Natl Toxicol*
395 *Program Tech Rep Ser.* 1992 Mar; 385: 1-212.
- 396 12. Smith JT, Schneider AD, Katchko KM, Yun C, Hsu EL. Environmental factors
397 impacting bone-relevant chemokines. *Front Endocrinol (Lausanne).* 2017 Feb 14;
398 8: 22. doi: 10.3389/fendo.2017.00022
- 399 13. Lehmann I, Roder-Stolinski C, Nieber K, Fischader G. In vitro models for the
400 assessment of inflammatory and immuno-modulatory effects of the volatile
401 organic compound chlorobenzene. *Exp Toxicol Pathol* (2008) 60(2–3):185–93. doi:
402 10.1016/j.etp.2008.01.009
- 403 14. Fischader G, Roder-Stolinski C, Wichmann G, Nieber K, Lehmann I. Release of
404 MCP-1 and IL-8 from lung epithelial cells exposed to volatile organic compounds.
405 *Toxicol In Vitro* (2008) 22(2):359–66. doi: 10.1016/j.tiv.2007.09.015

- 406 15. Zhou HL, Su GH, Zhang RY, Di DS, Wang Q. Association of volatile organic
407 compounds co-exposure with bone health indicators and potential mediators.
408 *Chemosphere*. 2022 Dec;308(Pt 1):136208. doi:
409 10.1016/j.chemosphere.2022.136208
- 410 16. Batterman S, Su FC, Li S, Mukherjee B, Jia C; HEI Health Review Committee.
411 Personal exposure to mixtures of volatile organic compounds: modeling and res
412 health eff Inst. 2014 Jun;(181):3-63.
- 413 17. Toxicity of Chloroform. *Prescrire Int*. 1998 Oct;7(37):149.
- 414 18. Cui Y, Zhou HL, Wei MH, Song WJ, Di DS, Zhang RY, et al. Multiple vitamin
415 co-exposure and mortality risk: a prospective research. *Clin Nutr*. 2022; 41(2): 337
416 -347. doi: 10.1016/j.clnu.2021.12.010
- 417 19. Lee S, Ko K, Shin S, Park HS, Hong N, Rhee Y. Adipopenia is associated with
418 osteoporosis in community-dwelling non-underweight adults independent of
419 sarcopenia. *Arch Osteoporos*. 2023 Mar 22;18(1): 44. doi:10.1007/s11657-023-
420 01233-x
- 421 20. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies
422 for osteoporosis. *Pharmacol Ther*. (2022) 237:108168. doi:
423 10.1016/j.pharmthera.2022.108168
- 424 21. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al.
425 Osteoporosis in the European Union: medical management, epidemiology and
426 economic burden. A report prepared in collaboration with the international
427 osteoporosis foundation (IOF) and the European Federation of Pharmaceutical

- 428 Industry Associations (EFPIA). *Arch Osteoporos.* (2013) 8:136. doi:
429 10.1007/s11657-013-0136-1
- 430 22. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et
431 al. The global prevalence of osteoporosis in the world: a comprehensive systematic
432 review and meta-analysis. *J Orthop Surg Res.* 2021 Oct 17;16(1):609. doi:
433 10.1186/s13018-021-02772-0
- 434 23. Konkle SL, Zierold KM, Taylor KC, Riggs DW, Bhatnagar A. National secular
435 trends in ambient air volatile organic compound levels and biomarkers of exposure
436 in the United States. *Environ Res.* (2020) 182:108991. doi:10.1016/j.envres.
437 2019.108991
- 438 24. Jain RB. Detection Rates, Trends in and factors affecting observed levels of
439 selected volatile organic compounds in blood among us adolescents and adults.
440 *Environ Toxicol Pharmacol.*(2017) 56:21-8.doi:10.1016/j.etap.2017.08.031
- 441 25. Jain RB. Distributions of selected urinary metabolites of volatile organic
442 compounds by age, gender, race/ethnicity, and smoking status in a representative
443 sample of US adults. *Environ Toxicol Pharmacol.* (2015) 40: 471-9.
444 doi:10.1016/j.etap.2015.07.018
- 445 26. Liu B, Jia C. Effects of exposure to mixed volatile organic compounds on the
446 neurobehavioral test performance in a cross-sectional research of US adults. *Int J*
447 *Environ Health Res.* (2015) 25: 349-63. doi:10.1080/09603123.2014.945514
- 448 27. Su FC, Jia C, Batterman S. Extreme value analyses of VOC exposures and risks: a
449 comparison of riopa and NHANES datasets. *atmospheric environ.* (2012) 62:97.

- 450 106. doi: 10.1016/j.atmosenv. 2012.06.038
- 451 28. Yan Z, Xiong X, Tao J, Wang S. Association of bone mineral density with
452 trichlorophenol: a population-based research. BMC musculoskelet disord. 2023
453 Mar 17. 24(1): 202. doi:10.1186/s12891-023-06323-y
- 454 29. Kirk AB, DeStefano A, Martin A, Kirk KC, Martin CF. A new interpretation of
455 relative importance on an analysis of per and polyfluorinated alkyl substances
456 (PFAS) exposures on bone mineral density. Int J Environ Res Public Health. 2023
457 Mar 3; 20 (5): 4539. doi:10.3390/ijerph20054539
- 458 30. Yang R, Chen Z, Hu Y. Associations of urinary polycyclic aromatic hydrocarbons
459 with bone mineral density at specific body sites in U.S. Adults, National Health
460 and Nutrition Examination Survey 2001 to 2004. Endocr Pract. 2022 Sep; 28(9):
461 867-874.10.1016/j.eprac.2022.06.008
- 462 31. Yang KD. Environmental hygiene (M). Beijing: people's medical publishing house,
463 2017.
- 464 32. Xu H, Cai J. Determination and risk assessment of disinfection by- products in
465 drinking water of S city(J). Water & Wastewater Engineering, 2020,56(9):37-40.
- 466 33. Zhao GP, Zou KT, Xu Q, Liu RX, Luo XH, Guan R. Distribution characteristics
467 and multi - pathways health risk assessment of trichloromethane in municipal water
468 of Xi'an.Modern Preventive Medicine(J). 2023,50(4):611-617.
- 469 34. Han JY,Ye BX,Zhang L. Health Risk Assessment of 10 pollutants in a city's
470 drinking water.Journal of environmental hygiene Jun(J).2019,9(3):203-209.
- 471 35. Wang C, Zhu Y, Long H, Ou M, Zhao S. Connection between blood manganese

- 472 and bone mineral density and bone mineral content in adults: a population-based
473 cross-sectional research. *PLoS One*. 2022 Oct 21; 17(10): e0276551.
474 doi:10.1371/journal.pone.0276551
- 475 36. Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and
476 strength of long term treatment with antiresorptive agents (estrogen and calcitonin),
477 human parathyroid hormone-(1-38), and combination therapy, assessed in aged
478 ovariectomized rats. *Endocrinology*. 1994 May;134(5):2126-34. doi:
479 10.1210/endo.134.5.8156913.
- 480 37. Liu J, Wang W, Tong QJ, et al. A comparative research of dual-energy X-ray bone
481 densitometry (DXA) and A comparative research of bone density measurement by
482 dual-energy X-ray bone densitometry (DXA) and quantitative CT (QCT)(J).
483 *Journal of Clinical Radiology*.2007, 26(5): 504- 507.
- 484 38. Yamauchi H, Kushida K, Yamazaki K, et al. Assessment of spine bone mineral
485 density in ovariectomized rats using DXA(J). *J Bone Miner Res*, 1995, 10(7):
486 1033- 1036. doi: 10.1002/jbmr.5650100707
- 487 39. Yin X, Zhao S, Xiang N, Chen J, Xu J, Zhang Y. Efficacy of Bushen Jiangu therapy
488 in the treatment of glucocorticoid-induced osteoporosis: A systematic review and
489 meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2023 Mar
490 17;102(11): e33278. doi: 10.1097/MD.00000000000033278
- 491 40. Deng HW, Xu FH, Davies KM, Heaney R, Recker RR. Differences in Bone
492 Mineral Density, Bone Mineral Content, and Bone Areal Size in Fracturing and
493 Non-fracturing Women, and Their Interconnections at the Spine and Hip.

- 494 Fracturing Women, and Their Interconnections at the Spine and Hip. *Journal of*
495 *bone and mineral metabolism*. 2002; 20(6): 358-66.doi:10.1007/s007740200052
- 496 41. Mohammadzadeh Akhlaghi N, Baradaran Mohajeri L, Fazlyab M. Tissue Necrosis
497 due to Chloroform: a Case Report. *Iran Endod J*. 2013 Fall;8(4):208-9.
- 498 42. Bonde JP, Toft G, Rylander L, Rignell-Hydbom A, Giwercman A, Spano M,
499 Manicardi GC, Bizzaro D, Ludwicki JK, Zvyezday V, Bonefeld-Jørgensen EC,
500 Pedersen HS, Jönsson BA, Thulstrup AM; INUENDO. Fertility and markers of
501 male reproductive function in Inuit and European populations spanning large
502 contrasts in blood levels of persistent organochlorines. *Environ Health Perspect*.
503 2008 Mar;116(3):269-77. doi: 10.1289/ehp.10700
- 504 43. Figa-Talamanca I. Occupational risk factors and reproductive health of women.
505 *Occup Med (Lond)* 2006; 56: 521–531. doi: 10.1093/occmed/kql114
- 506 44. Hassani S, Namvar M, Ghoreishvandi M, Attarchi M, Golabadi M, Seyedmehdi
507 SM, Khodarahmian M. Menstrual disturbances and hormonal changes in women
508 workers exposed to a mixture of organic solvents in a pharmaceutical company.
509 *Med J Islam Repub Iran*. 2014 Dec 27; 28:156.
- 510 45. Begić A, Begić A, Arnautović-Halimić A. Influence of thyroid hormones on bone
511 density. *Med Glas (Zenica)*. 2020 Feb 1;17(1):35-40. doi: 10.17392/1056-20

512 **Supporting information**

513 **S1 Table Related demographic characteristics of participants included in**


514 **NHANES from 2009 to 2010 and 2013 to 2014 and 2017-2020.** Means with

515 standard deviation (SD) were used for continuous characteristic variables and


516 categorical variables were expressed as frequencies. Differences in categorical
517 variables between exposed groups were analyzed by Kruskal Wallis test or Mann
518 Whitney test. Spearman correlation analysis was used to analyze the differences of
519 continuous variables between groups.

520 (EXCEL)


521 **S2 Table Blood chloroform and area, BMC, and BMD based on chloroform**
522 **tristimulus.** Data are expressed as means (standard deviation, SD). BMC, bone mineral
523 content, BMD, bone mineral density, Area (cm²), BMC (g), BMD (g/cm²). (EXCEL)



Figure



Figure



Figure